Kumamoto, Japan

Kohsuke Hazeyama

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 2 CIPO patents. Top assignee: Km Biologics Co., Ltd.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kohsuke Hazeyama: Innovator in Vaccine Development

Introduction

Kohsuke Hazeyama is a prominent inventor based in Kumamoto, Japan. He has made significant contributions to the field of vaccine development, particularly in addressing congenital infections. His innovative work has the potential to impact public health positively.

Latest Patents

Kohsuke Hazeyama holds a patent for a vaccine aimed at preventing or treating congenital infection with cytomegalovirus (CMV). The objective of this invention is to provide an effective vaccine capable of preventing and treating congenital infection with CMV. The vaccine comprises a CMV envelope glycoprotein B (gB protein) antigen and a pentamer antigen. This patent highlights his commitment to advancing medical science and improving health outcomes.

Career Highlights

Kohsuke Hazeyama is associated with Km Biologics Co., Ltd., where he continues to work on innovative solutions in the field of biotechnology. His dedication to research and development has led to advancements that could benefit many individuals affected by CMV.

Collaborations

Some of his notable coworkers include Masaharu Torikai and Hiroaki Mori. Their collaboration in research and development has contributed to the success of their projects and innovations.

Conclusion

Kohsuke Hazeyama's work in vaccine development exemplifies the importance of innovation in addressing health challenges. His contributions, particularly in the realm of congenital infections, are commendable and reflect a commitment to improving public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…